Company
United StatesPublic company, NASDAQ: ALNYAlnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Cambridge, MA – FDA Inspections
Inspection records and compliance data for Alnylam Pharmaceuticals, Inc. in Cambridge, Massachusetts. 3 FDA inspections on record, 1 Form 483, last inspected September 09, 2022. Publicly traded as NASDAQ: ALNY.
Company Profile
This profile covers Alnylam Pharmaceuticals, Inc. based in Cambridge, Massachusetts, United States.
FDA Inspection History
- FDA inspections
- 3
- OAI
- 0
- VAI
- 1
- NAI
- 2
- Form 483s
- 1
- Warning letters
- 0
First inspected April 25, 2018. Last inspected September 9, 2022.
FDA inspections (3)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| September 9, 2022 | NAI | Human Drugs · Bioresearch Monitoring | 1181120 |
| September 18, 2019 | NAI | Human Drugs · Bioresearch Monitoring | 1107254 |
| April 25, 2018 | VAI | Human Drugs · Bioresearch Monitoring | 1050979 |
FDA documents
EIRs (1)
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Alnylam Pharmaceuticals, Inc.
Stock ticker
ALNY
Exchange
NASDAQ
Share price
$156.65
Market cap
$21.0B
Price as of
November 13, 2026
FEI Number
3004080452
Address
300 3rd St, Cambridge, Massachusetts 02142, United States
Country
United States
ID: 918c30c3-22a5-436f-88c1-6af91b2c575a